The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
Targeted therapies for certain types of cancer and rare disease offer new hope for these patient populations. But how can we ensure that these treatments are also developed with minority communities in mind?
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Minority groups get left out of clinical trials and studies for many reasons, including lack of access, awareness and trust in the healthcare system. But, according to panelists at MedCity INVEST Precision Medicine, researchers along with patient advocates can help tackle these hurdles by working together and being intentional in their approach.
PatientsLikeMe was in a haste to find a buyer after regulators at the Committee on Foreign Investment in the U.S. (CFIUS), forced its majority shareholder Shenzhen, China-based iCarbonX to divest their holdings in the startup.
Cambridge, Massachusetts-based PatientsLikeMe is being forced to find a new buyer for the company because of the iCarbonX divesture mandated by U.S. regulators.
AI is a topic that fuels the passions of healthcare entrepreneurs but is it also a distraction from where the real pain points in healthcare are? A panel discussion on AI at the J.P. Morgan Healthcare Conference wrestled with the issue.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
A recent poll from PatientsLikeMe asked 2,755 patients with chronic or progressive degenerative conditions about their thoughts on healthcare in America.
Reputation.com and Arcadia Healthcare Solutions also scooped up investments of $20 million and $30 million, respectively.
The rule seeks to clarify the Food and Drug Administration Amendments Act of 2007, which left significant room for interpretation.
Go big or go home, healthcare. 2016 is the year to make big things happen.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pharmaceutical companies are turning to ethnographers to get a better appreciation for the diversity of the patient experience.
PatientsLikeMe and the FDA will explore the potential of patient-generated data to inform regulatory review activities related to risk assessment and risk management.
A collaboration between PatientsLikeMe and Partners HealthCare hopes to give the integrated health system's patients greater access to the patient community network and gain valuable insights on patient engagement.
A study by a team of researchers from Biogen and PatientsLikeMe to quantify physical activity of patients with multiple sclerosis between doctor appointments released some details on the patient experience of the study. It found the experience resonated with many of the participants keen to use the FitBit One to monitor their own activity. Participants […]
In an effort to tap patient communities for insights on drug development, AstraZeneca has inked a five-year deal with PatientsLikeMe, according to a company statement. Ed Godber, executive vice president of Life Sciences Ventures at PatientsLikeMe, said unlike most of its pharma collaborations, which have been with U.S. affiliates of drug companies, “this one integrates […]